Introduction
Visceral adiposity has been shown to play an important role in the development of an unfavorable meta-bolic and cardiovascular risk profile 1) . Increased waist circumference has been accepted as a surrogate measure of visceral abdominal obesity and a marker of an adverse metabolic profile associated with high cardiovascular risk 2) . However, waist circumference may be confounding, particularly in severely obese people due to large amount of subcutaneous fat 3) 2 ciency and scheduled for vitamin D replacement therapy between June 2012-January 2013 according to the 2011 guidelines of The Endocrine Society 19, 20) and 31 control subjects (age: 34.48 8.16 years) were included in this study. Patients with atherosclerotic vascular disease, major risk factors for atherosclerotic diseases (e.g., diabetes mellitus, hypertension, dyslipidemia, a history of smoking, and a family history for premature atherosclerosis), chronic inflammatory disease, malignancy, a history of treatment with drugs affecting vascular function (e.g., statins, ACEi/ARBs, nitrate, CCBs, and oral contraceptives), or acute or chronic infections were excluded. This study was approved by the local ethics committee and was carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
Study Protocol
The medical history and detailed physical examination findings including height, weight, and waist circumference were recorded for all patients. In addition to routine complete blood cell count and biochemistry tests, the left ventricular systolic and diastolic functions, chamber dimensions, valvular functions, and EAT thickness were evaluated with TTE in the study population.
Patients with a serum concentration of 25(OH) D 20 ng/mL were defined as vitamin D deficient. Vitamin D3 treatment with 50,000 IU/week for 8 weeks and a maintenance dose of 1,500-2,000 IU/day were administered to vitamin D deficient patients in accordance with the 2011 guidelines of The Endocrine Society 19, 20) . Subjects who underwent vitamin D replacement therapy were re-evaluated for the same parameters at the 6-month follow-up. visceral fat depots 4) . EAT is the visceral adipose tissue of the heart and has been proposed as a new marker of visceral adiposity in previous studies 4, 5) . It is a metabolically active organ that generates various bioactive molecules that are directly involved in inflammation and known to modulate vascular and myocardial functions, including adiponectin, tumor necrosis factor-(TNF-), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) 6, 7) . EAT thickness measured with transthoracic echocardiography (TTE) has been demonstrated to have a strong correlation with abdominal adiposity measured with computed tomography (CT) or magnetic resonance imaging (MRI) 5, 8, 9) .
Several clinical studies have shown that EAT thickness is significantly and independently related with metabolic syndrome 5, 10, 11) . EAT, measured with either TTE or CT, has also been associated with the presence and increased severity of coronary artery disease (CAD), and the presence of coronary calcification in a large number of studies 8, 12) . Furthermore, EAT thickness has been demonstrated to be a stronger predictor for CAD than any other visceral adipose tissue located in the body 13) . Vitamin D is a secosteroid hormone that plays a crucial role in mineral homeostasis and skeletal health 14) . Vitamin D has also been implicated in a wide range of systemic diseases, including autoimmune disorders, cancer, diabetes mellitus, and cardiovascular diseases 15, 16) . The serum 25(OH)D level, which is considered the best indicator of vitamin D status 14) , is found to be inversely correlated with measures of obesity, including body mass index (BMI), fat mass, and waist circumference 17, 18) . In addition, we have previously demonstrated impaired endothelial functions in vitamin D deficient premenopausal women and improvement following vitamin D replacement 19) . However, the relationship between vitamin D status and EAT thickness, which is a novel marker of visceral adiposity, has not yet been demonstrated.
Aim
The objective of this study was to investigate the relationship between vitamin D deficiency and EAT thickness in otherwise healthy premenopausal women.
Methods

Study Population
Thirty-one premenopausal women (age: 33.10 5.70 years) who were diagnosed with vitamin D defi- 3 measured at the point on the free wall of the right ventricle along the midline of the ultrasound beam, perpendicular to the aortic annulus, which was used as an anatomical landmark for this view (Fig. 1) . The average value of three cardiac cycles from each echocardiographic view was taken into account. Intraobserver variability testing for repeated EAT thickness measurements from 25 subjects revealed an intra-class correlation coefficient of 0.961 (p 0.001).
Statistical Analysis
Normally distributed parameters were presented as mean standard deviation and skewed parameters were expressed as median (interquartile range). Descriptive data were presented as frequencies (number and percentage) and compared using the chi-square test. Univariate analyses were performed on continuous variables with the use of the independent Student's t -test for normally distributed variables and the MannWhitney U test for non-normally distributed data. For comparing continuous variables (values before and after replacement) with normal and non-normal distribution, the dependent t -test and the Wilcoxon tests were used, respectively. The Spearman correlation
Biochemical Analysis of 25-Hydroxyvitamin D
Venous blood samples were obtained from all participants in the morning following overnight fasting and analyzed in the Hacettepe University Laboratories. The plasma 25(OH)D levels were measured with a high pressure liquid chromatography device (Shimadzu LC-20AT) via chromatographic methods using the ImmuChrom 25(OH)D kit. The analytical detection limit for the kit was 2.3 ng/mL and reference ranges were 10-60 ng/mL in the winter and 20-120 ng/mL in the summer according to the manufacturer's instructions.
Epicardial Adipose Tissue Thickness Measurement
Each subject underwent a transthoracic 2D guided M-mode echocardiogram using commercially available equipment (Vivid S6; GE Healthcare, Horten, Norway). Standard parasternal views were obtained in the left lateral decubitus position. Epicardial fat was identified as the echo-free space between the outer wall of the myocardium and the visceral layer of pericardium. EAT thickness was measured perpendicularly on the free wall of the right ventricle at end-systole in three cardiac cycles. Maximum EAT thickness was were performed to determine the factors influencing EAT thickness ( Table 2) . EAT thickness was found to be positively correlated with BMI (r 0.287, p 0.029) and waist circumference (r 0.421, p 0.001), whereas it was negatively correlated with 25(OH)D levels (r 0.559, p 0.001) ( Table 2 ). In the robust regression analysis, only waist circumference ( 0.031 [0.005-0.057], p 0.020) (Fig. 2a) and 25(OH)D levels ( 0,020 [( 0,028) ( 0,013)], p 0.001) (Fig. 2b ) were independent predictors of EAT thickness.
Effects of Vitamin D Replacement Therapy
The effects of vitamin D replacement therapy on the patient group are presented in Table 3 . At the 6-month follow-up, the patients who received vitamin D replacement therapy had significantly higher serum 25(OH)D levels (p 0.001). The vitamin D replacement therapy did not have a significant effect on any other baseline characteristics, including BMI, renal function, WBC count, serum lipid levels, fasting blood glucose, TSH, calcium and phosphorus, and left ventricular systolic function (p 0.05). The vitamin D replacement therapy also did not significantly alter EAT thickness (p 0.05) ( Table 3) .
Discussion
The results of this study show that vitamin D deficient premenopausal women had increased visceral analysis was used to demonstrate the correlation between EAT thickness and baseline characteristics. A Linear regression analysis was used for identifying factors that were independently correlated with EAT thickness. All statistical analyses were performed using SPSS statistical software (version 21.0; SPSS Inc., Chicago, Illinois, USA) and a two-tailed p 0.05 was considered to be statistically significant.
Results
Study Population
The baseline clinical, biochemical, and echocardiographic parameters of the groups are presented in Table 1 . The patient and control groups were similar with respect to age, BMI, and waist circumference ( Table 1 , p 0.05). Furthermore, there were no significant differences in the baseline renal function, white blood cell (WBC) counts, serum lipid levels, fasting blood glucose, thyroid stimulating hormone (TSH), calcium and phosphorus levels, and left ventricular systolic function between two groups (Table 1, p 0.05). The baseline serum 25(OH)D levels were lower and EAT thickness was increased in the patient group compared with the control group (Table 1, p 0.001).
Correlation Analyses
Univariate and multivariate correlation analyses It has been proposed that 1,25(OH)2D3 inhibits 21, 22) 3T3-L1 preadipocyte differentiation in a dose-dependent manner, secondary to its inhibitory effect on the expression of adipogenic transcription factor genes (e.g., C/EBPb, PPARg, and SREBP1) and of the downstream adipocyte markers (e.g., lipoprotein lipase, adipocyte lipid-binding protein 2, and fatty acid synthase) 22, 23) . Furthermore, a more specific effect of 1,25(OH)2D3 on the WNT/ -catenin signal pathway, which is known to have a role in maintaining preadipocytes in their undifferentiated state, has been suggested 23, 24) . In addition, 1,25(OH)2D3 has also been shown to inhibit the differentiation of mouse bone marrow stromal cells (BMSCs) into adipocytes by the suppression of dickkopf1 (DKK1) and secreted frizzled-related protein 2 (SFRP2) expression levels via VDR-mediated WNT signaling 24, 25) . Conversely, in some studies, 1,25(OH)2D3 treatment of mesencyhmal stem cells has resulted in the promotion of dose-dependent differentiation toward an adipocytic phenotype via increasing PPAR , lipoprotein lipase, and adipocyte-binding protein 2 (AP2) mRNA levels [25] [26] [27] . In human tissue, 1,25(OH)2D3 has been shown to promote the differentiation of already committed subcutaneous preadipocytes through an increased expression of adipogenic markers FABP4 and LPL 27, 28) . Serum 25(OH)D levels have been found to be inversely correlated with measures of obesity, including BMI, fat mass, and waist circumference, in previous clinical studies 17, 18) . It has also been shown that the negative influence of obesity on the serum 25(OH)D adiposity as reflected by increased EAT thickness but was not accompanied with any significant difference in BMI or waist circumference as compared to the control group. Of the baseline characteristics, waist circumference and vitamin D status were independently correlated with EAT thickness. A 6-month vitamin D supplementation in accordance with the 2011 guidelines of The Endocrine Society resulted in a significant improvement in the vitamin D status; however, this was not accompanied by a significant change in EAT thickness. To the best of our knowledge, this is the first study to reveal the effects of vitamin D deficiency and replacement on visceral adiposity as reflected by EAT.
There are several studies suggesting a relationship between local inflammation in EAT and coronary atherosclerosis. Hirata et al. 21) previously demonstrated enhanced infiltration of macrophages and expression of pro-and anti-inflammatory cytokines in the EAT measurements of patients with CAD compared with those in non-CAD patients. Shimabukuro et al. 22) have also shown a strong correlation between CAD and EAT volume and macrophage and cytokine/adipocytokine signals in EAT. These studies highlight the importance of EAT in the pathogenesis of atherosclerosis. Therefore, identifying the factors affecting EAT thickness may have a significant role in the prevention of atherosclerosis and related events.
Data regarding the role of vitamin D and its receptor (VDR) on adipogenesis is contradictory due to its diverse effects on various levels of adipogenesis. ever, earlier studies performed in 3T3-L1 and human adipocytes have demonstrated results favoring inflammatory cytokine expression 30, 31) . Still, recent evidence has focused on the involvement of 1,25(OH)2D3 in the regulation of adipose tissue inflammation by reducing the proinflammatory cytokines secreted from adipose tissue. In human subcutaneous adipose tissue fragments, 1,25(OH)2D3 has been demonstrated to reduce IL-1 -induced expression of the inflammatory genes MCP-1, IL-6, and IL-8 [31] [32] [33] . Although we have demonstrated that the vitamin D level is related with EAT thickness, further studies are required to show the impact of vitamin D on the inflammatory activity of EAT.
Study Limitations
There are some limitations associated with our study. Currently, cardiac MRI and CT are the gold standard diagnostic methods for assessing EAT thickness; however, the widespread use of these methods for the assessment of EAT is not practical. Another limitation in our study is the small sample size. Further studies on a larger cohort of patients are necessary to confirm our findings. levels may be mostly attributable to the visceral fat area, irrespective of BMI 28, 29) . In our study, vitamin D deficient patients had increased EAT thickness, supporting the hypothesis that vitamin D is linked with an inhibition of adipogenesis. Furthermore, we observed that increased EAT thickness in vitamin D deficient patients was positively correlated with waist circumference, another marker of visceral adiposity, irrespective of BMI.
In a double-blind, placebo-controlled trial, dietary supplementation with calcium and vitamin D for 16 weeks was associated with a beneficial reduction of visceral fat in overweight and obese adults 29, 30) . However, our study failed to demonstrate an improvement in EAT thickness or waist circumference (as markers of visceral adiposity) following 6-month vitamin D replacement therapy. Furthermore, a larger study population and longer duration of vitamin D replacement therapy and follow-up may be required to observe significant changes.
Current data on the effects of 1,25(OH)2D3 on adipose tissue inflammation is also conflicting. Several in vitro studies in the mouse 3T3-L1 cell line and human adipocytes have demonstrated that 1,25(OH)2D3 inhibits chronic inflammation in adipose tissue. How- 
Conclusion
This study demonstrates for the first time that vitamin D deficiency is associated with a significant increase in EAT thickness in premenopausal women; however, a net beneficial response to adequate replacement therapy was not observed during the short period of therapy in our study. Further studies with larger populations and longer periods of replacement therapy and follow-up may be useful to demonstrate the potential beneficial effects of vitamin D replacement therapy on epicardial adiposity.
